<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027495</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067916</org_study_id>
    <secondary_id>P30CA046592</secondary_id>
    <secondary_id>CCUM-9941</secondary_id>
    <secondary_id>NCI-P00-0144</secondary_id>
    <nct_id>NCT00027495</nct_id>
  </id_info>
  <brief_title>Curcumin for the Prevention of Colon Cancer</brief_title>
  <official_title>Phase I Pharmacokinetic Trial of Curcuminoids Administered in a Capsule Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development of cancer. Curcumin may be effective in preventing the development of colon&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: Phase I trial to determine the dose amount of curcumin that can be tolerated to help&#xD;
      in preventing colon cancer in healthy men and women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of curcumin as a chemopreventive agent of&#xD;
           colon cancer in healthy subjects.&#xD;
&#xD;
        -  Determine if tolerable doses of this agent in uniformly milled formulation capsules are&#xD;
           bioavailable in these subjects.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this agent and two metabolites at the MTD and next&#xD;
           lower escalated dose in these subjects.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study followed by a pharmacokinetic study.&#xD;
&#xD;
      Patients receive a single oral dose of curcumin followed by a standard fatty meal.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of curcumin until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose&#xD;
      limiting toxicities. Once the MTD is determined, additional patients are accrued to receive&#xD;
      curcumin in the pharmacokinetic phase of the study.&#xD;
&#xD;
      Patients are followed at 24, 36, 48, and 72 hours.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for the dose escalation phase and&#xD;
      then 12 additional patients will be accrued for the pharmacokinetic phase of this study&#xD;
      within 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>curcumin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Healthy men and women age 18 and over&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 4,000/mm3&#xD;
&#xD;
          -  Hemoglobin greater than 12 g/dL&#xD;
&#xD;
          -  Platelet count greater than 120,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  ALT/AST less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase less than 1.5 times ULN&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.7 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior cancer except surgically resected basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No history of peptic ulcer disease, gastrointestinal bleeding from gastric or duodenal&#xD;
             ulcers, or gastrin secreting tumors&#xD;
&#xD;
          -  No history of unreliability or noncompliance (missing pretreatment appointment more&#xD;
             than twice)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 14 days since prior steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 14 days since prior curcumin (turmeric) rich foods&#xD;
&#xD;
          -  At least 14 days since prior nonsteroidal antiinflammatory drugs (NSAIDs)&#xD;
&#xD;
          -  No chronic medications (i.e., daily for more than 28 days) except for oral&#xD;
             contraceptives&#xD;
&#xD;
          -  No concurrent coumadin or other anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean E. Brenner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0930</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

